$TENX
TENAX THERAPEUTICS, INC. Stock $tenx

$tenx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000156827621002533 Filed on November 15, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.296M	$2.640M	$1.271M
YoY Change	18.36%	125.11%	46.26%
% of Gross Profit
Research & Development	$915.6K	$1.162M	$693.2K
YoY Change	2.88%	10.45%	-45.62%
% of Gross Profit
Depreciation & Amortization	$1.080K	$1.010K	$1.000K
YoY Change		1.0%
% of Gross Profit
Operating Expenses	$3.212M	$3.802M	$1.965M
YoY Change	13.49%	70.88%	-8.37%
Operating Profit		$3.802M	$1.965M
YoY Change		70.88%	-8.37%
Interest Expense	$0.00	$0.00	$336.00
YoY Change
% of Operating Profit		0.0%	0.02%
Other Income/Expense, Net	-$508.4K	$3.640K	-$247.8K
YoY Change		-63.6%	-11895.34%
Pretax Income	-$3.720M	-$3.799M	-$1.717M
YoY Change	31.46%	71.11%	-20.14%
Income Tax
% Of Pretax Income
Net Earnings	-$3.720M	$3.799M	$1.717M
YoY Change	31.46%	-271.08%	-179.99%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$147.3K	-$150.7K	-$99.72K
COMMON SHARES
Basic Shares Outstanding	25.21M shares	25.20M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.584M	$8.354M	$3.871M
YoY Change	-16.78%	-4.09%	-14.91%
Cash & Equivalents	$5.584M	$8.354M	$1.671M
Short-Term Investments	$0.00	$0.00	$2.200M
Other Short-Term Assets	$105.1K	$229.2K	$349.9K
YoY Change	31.35%	20.61%	-46.99%
Inventory
Prepaid Expenses	$105.1K	$229.2K	$349.9K
Receivables
Other Receivables
Total Short-Term Assets	$5.689M	$8.583M	$2.532M
YoY Change	-16.28%	-3.56%	-51.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.108K	$6.489K	$5.821K
YoY Change	19.02%	-92.79%	-95.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.435K	$8.435K	$8.435K
YoY Change	0.0%	-15.65%	-15.65%
Total Long-Term Assets	$303.2K	$328.4K	$353.0K
YoY Change	314.34%	228.37%	152.11%
TOTAL ASSETS
Total Short-Term Assets	$5.689M	$8.583M	$2.532M
Total Long-Term Assets	$303.2K	$328.4K	$353.0K
Total Assets	$5.992M	$8.912M	$2.885M
YoY Change	-12.76%	-0.98%	-46.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$859.6K	$776.2K	$791.9K
YoY Change	13.43%	-26.07%	-49.23%
Accrued Expenses	$704.3K	$685.1K	$383.1K
YoY Change	-43.23%	128.37%	-26.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Total Short-Term Liabilities	$1.564M	$1.461M	$1.175M
YoY Change	-26.19%	5.9%	-46.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$183.6K	$211.6K	$239.0K
YoY Change
Total Long-Term Liabilities	$183.6K	$211.6K	$239.0K
YoY Change	47.86%	0.76%	70.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.564M	$1.461M	$1.175M
Total Long-Term Liabilities	$183.6K	$211.6K	$239.0K
Total Liabilities	$1.748M	$1.673M	$1.414M
YoY Change	-22.09%	5.22%	-39.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$278.5M	-$275.3M	-$271.5M
YoY Change	13.2%
Common Stock	$2.521K	$2.520K	$273.0M
YoY Change	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.245M	$7.239M	$1.471M
YoY Change
Total Liabilities & Shareholders Equity	$5.992M	$8.912M	$2.885M
YoY Change	-12.76%	-0.98%	-46.07%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021 Q2
OPERATING ACTIVITIES
Net Income	-$3.720M	$3.799M	$1.717M
YoY Change	31.46%	-271.08%	-179.99%
Depreciation, Depletion And Amortization	$1.080K	$1.010K	$1.000K
YoY Change		1.0%
Cash From Operating Activities	-$2.768M	-$3.022M	-$1.846M
YoY Change	39.82%	26.42%	-17.21%
INVESTING ACTIVITIES
Capital Expenditures	-$1.700K	-$1.670K	-$1.880K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$513.2K	-$15.36K
YoY Change		5032.2%	-176.8%
Cash From Investing Activities	-$1.700K	$511.5K	-$17.23K
YoY Change		5015.4%	-186.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$244.7K
YoY Change
Cash From Financing Activities	0.000	9.193M	4.650K
YoY Change		40.78%	-99.76%
NET CHANGE
Cash From Operating Activities	-2.768M	-3.022M	-1.846M
Cash From Investing Activities	-1.700K	511.5K	-17.23K
Cash From Financing Activities	0.000	9.193M	4.650K
Net Change In Cash	-2.770M	6.683M	-1.859M
YoY Change	39.91%	61.03%	588.45%
FREE CASH FLOW
Cash From Operating Activities	-$2.768M	-$3.022M	-$1.846M
Capital Expenditures	-$1.700K	-$1.670K	-$1.880K
Free Cash Flow	-$2.767M	-$3.020M	-$1.844M
YoY Change	39.73%	26.35%	-17.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
CY2020Q4	us-gaap	Liabilities Liabilities	2243129	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q3	us-gaap	Notes Payable NotesPayable	0	USD
CY2020Q4	us-gaap	Notes Payable NotesPayable	124166	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	211590	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	124166	USD
CY2021Q3	us-gaap	Liabilities Liabilities	1672951	USD
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25206914	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8354075	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6250241	USD
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	462687	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	229152	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	82578	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	8583227	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	6795506	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	313443	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58778	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6489	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5972	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8435	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8435	USD
CY2021Q3	us-gaap	Assets Assets	8911594	USD
CY2020Q4	us-gaap	Assets Assets	6868691	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	776247	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	757856	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	685114	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1240616	USD
CY2021Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	120491	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1461361	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2118963	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	211590	USD
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	9999790	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25201312	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12619369	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	2520	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1262	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	282519752	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	250644197	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-70	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275283631	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-246019827	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	7238643	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4625562	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8911594	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6868691	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2639920	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1172725	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5284658	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3364890	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1162370	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1052398	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24231794	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3669761	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3802290	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	2225123	USD
	us-gaap	Operating Expenses OperatingExpenses	29516452	USD
	us-gaap	Operating Expenses OperatingExpenses	7034651	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	3802290	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2225123	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	29516452	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	7034651	USD
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	USD
CY2020Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	610	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	949	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1016	USD
CY2021Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-3642	USD
CY2020Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-5298	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-253597	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-14038	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	3798648	USD
	us-gaap	Net Income Loss NetIncomeLoss	29263804	USD
	us-gaap	Net Income Loss NetIncomeLoss	7021629	USD
CY2021Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-276	USD
CY2020Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	1171	USD
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-72	USD
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-445	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3798372	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2221606	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	29263732	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7021184	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.54
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25201312	shares
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12427355	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19017311	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9590741	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3772497	USD
CY2020Q1	tenx	Common Stock And Pre Funded Warrants Sold Net Of Offering Costs Amount CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount	2130005	USD
CY2020Q1	tenx	Compensation On Options Issued CompensationOnOptionsIssued	72376	USD
CY2020Q1	tenx	Common Stock Issued For Services Rendered Amount CommonStockIssuedForServicesRenderedAmount	100000	USD
CY2020Q1	tenx	Common Stock Issued For Convertible Preferred Stock Amount CommonStockIssuedForConvertiblePreferredStockAmount	0	USD
CY2020Q1	tenx	Exercise Of Pre Funded Warrants Amount ExerciseOfPreFundedWarrantsAmount	40	USD
CY2020Q1	tenx	Unrealized Loss On Marketable Securities UnrealizedLossOnMarketableSecurities	-1622	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2654644	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	3418652	USD
CY2020Q2	tenx	Compensation On Options Issued CompensationOnOptionsIssued	63166	USD
CY2020Q2	tenx	Exercise Of Pre Funded Warrants Amount ExerciseOfPreFundedWarrantsAmount	121	USD
CY2020Q2	tenx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1690543	USD
CY2020Q2	tenx	Unrealized Gain On Marketable Securities UnrealizedGainOnMarketableSecurities	3238	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2146550	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	3029170	USD
CY2020Q3	tenx	Compensation On Options Issued CompensationOnOptionsIssued	63161	USD
CY2020Q3	tenx	Unrealized Loss On Marketable Securities UnrealizedLossOnMarketableSecurities	-1171	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-2220435	USD
CY2020Q3	tenx	Common Stock And Pre Funded Warrants Sold Net Of Offering Costs Amount CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount	6532979	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	7403704	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4625562	USD
CY2021Q1	tenx	Common Stock And Preferred Stock Issued For Asset Acquisition Amount CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount	21582331	USD
CY2021Q1	tenx	Compensation On Options Issued CompensationOnOptionsIssued	91609	USD
CY2021Q1	tenx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	544651	USD
CY2021Q1	tenx	Unrealized Loss On Marketable Securities UnrealizedLossOnMarketableSecurities	-332	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-23748140	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	3095681	USD
CY2021Q2	tenx	Common Stock Issued For Convertible Preferred Stock Amount CommonStockIssuedForConvertiblePreferredStockAmount	0	USD
CY2021Q2	tenx	Compensation On Options Issued CompensationOnOptionsIssued	92339	USD
CY2021Q2	tenx	Unrealized Gain On Marketable Securities UnrealizedGainOnMarketableSecurities	128	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1717016	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1471132	USD
CY2021Q3	tenx	Common Stock And Pre Funded Warrants Sold Net Of Offering Costs Value CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsValue	9192624	USD
CY2021Q3	tenx	Compensation On Options Issued CompensationOnOptionsIssued	373259	USD
CY2021Q3	tenx	Unrealized Gain On Marketable Securities UnrealizedGainOnMarketableSecurities	276	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	7238643	USD
	us-gaap	Profit Loss ProfitLoss	-29263804	USD
	us-gaap	Profit Loss ProfitLoss	-7021629	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3037	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3098	USD
	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	949	USD
	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	1016	USD
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	79115	USD
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	82163	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-247233	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	tenx	Issuance Of Common Stock And Preferred Stock For Asset Acquisition IssuanceOfCommonStockAndPreferredStockForAssetAcquisition	21582331	USD
	tenx	Issuance Of Common Stock And Preferred Stock For Asset Acquisition IssuanceOfCommonStockAndPreferredStockForAssetAcquisition	0	USD
	tenx	Issuance And Vesting Of Compensatory Stock Options And Warrants IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants	557207	USD
	tenx	Issuance And Vesting Of Compensatory Stock Options And Warrants IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants	198703	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	75000	USD
	tenx	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	9427	USD
	tenx	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	5078	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-146574	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	616676	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-644311	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1185136	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-17892	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-60379	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8087748	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7285410	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	345540	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	458438	USD
	tenx	Sale Of Marketable Securities SaleOfMarketableSecurities	803401	USD
	tenx	Sale Of Marketable Securities SaleOfMarketableSecurities	475041	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3554	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	454307	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16603	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9192624	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	8662985	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	544651	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1690704	USD
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	0	USD
CY2021Q3	tenx	Common Stock Par Or Stated Value Per Shares CommonStockParOrStatedValuePerShares	0.0001
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8235532	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6250241	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4905993	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8354075	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	333779	USD
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	244657	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9737275	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10598346	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2103834	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3329539	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In preparing the unaudited condensed consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.</p>
	us-gaap	Partners Capital Account Units Sold In Private Placement PartnersCapitalAccountUnitsSoldInPrivatePlacement	4773269	shares
	us-gaap	Accelerated Share Repurchases Initial Price Paid Per Share AcceleratedShareRepurchasesInitialPricePaidPerShare	2.095
	tenx	Available For Sale Securities Gross Realized Gains Losses Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds	10000000.0	USD
CY2021Q3	tenx	Common Stock Shares Issue CommonStockSharesIssue	25201312	shares
	tenx	Schedule Of Investments In Marketable Securities ScheduleOfInvestmentsInMarketableSecurities	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of September 30, 2021 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 30px; TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,354,075</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,354,075</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2021Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	8354075	USD
CY2021Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	0	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	6250241	USD
CY2020Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	462687	USD
CY2021Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	43033	USD
CY2020Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	43033	USD
CY2021Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	21259	USD
CY2020Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	23307	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64292	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	66340	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	57803	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	60368	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6489	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5972	USD
CY2020Q3	us-gaap	Depreciation Depreciation	1000	USD
	us-gaap	Depreciation Depreciation	3000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	104298	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	60379	USD
CY2021Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	211590	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	315888	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	60379	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	462444	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	860629	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	118372	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	319608	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	104298	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	60379	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	685114	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1240616	USD
CY2015Q3	us-gaap	Area Of Land AreaOfLand	5954	sqft
	tenx	Lease Term Period LeaseTermPeriod	P64Y
	us-gaap	Description Of Lessee Leasing Arrangements Operating Leases DescriptionOfLesseeLeasingArrangementsOperatingLeases	The Company has two five-year options to extend the Lease and a one-time option to terminate the Lease thirty-six months after the commencement of the initial term if no additional space became available. On April 2, 2021, the Company negotiated a 3-year extension to the existing lease term, commencing
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	125034	USD
	tenx	Percentage Of Annual Increase In Rent PercentageOfAnnualIncreaseInRent	0.025	pure
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	31259	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	126612	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	129797	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	65702	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	353370	USD
CY2021Q3	tenx	Less Imputed Interest LessImputedInterest	-37482	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	315888	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
	us-gaap	Lease Cost LeaseCost	100058	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6997	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	21582331	USD
CY2021Q3	tenx	Number Of Warrants Outstanding Beginning NumberOfWarrantsOutstandingBeginning	20928767	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q2	tenx	Ppp Loan Amount PppLoanAmount	244657	USD
CY2021Q2	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	244657	USD
CY2021Q2	tenx	Debt Instrument Decrease Forgiveness Accrued Interest DebtInstrumentDecreaseForgivenessAccruedInterest	2576	USD
	tenx	Common Stock Acquired CommonStockAcquired	1892905	shares
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	10232000	shares
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1212492	shares
	tenx	Percentage Of Preferred Stock Carries Voting Rights PercentageOfPreferredStockCarriesVotingRights	0.10	pure
	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	3369371	USD
	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	18212960	USD
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	21582331	USD
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	0	USD
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	150000	USD
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	150000	USD
	tenx	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	21732331	USD
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12619369	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10033274	shares
CY2020Q1	tenx	Common Stock Shares Issue CommonStockSharesIssue	750000	shares
CY2020Q1	tenx	Warrant To Purchase Of Common Stock Exercise Price WarrantToPurchaseOfCommonStockExercisePrice	1.1651
CY2020Q4	tenx	Number Of Warrants Outstanding Beginning NumberOfWarrantsOutstandingBeginning	16599079	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.29
	tenx	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentIssued	5131264	USD
	tenx	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Issued In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice	2.00
	tenx	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised	-801576	shares
	tenx	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	1.54
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.45
	tenx	Shares Available For Grant Table Textblock SharesAvailableForGrantTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Available for </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Grant</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Balances, at December 31, 2020</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;text-align:right;">356,500</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Additional shares reserved</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;text-align:right;">750,000</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;text-align:right;">(378,750</td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options cancelled/forfeited </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">91,000</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balances, at September 30, 2021</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;text-align:right;">818,750</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>

Files In Submission

Name	View Source	Status
0001568276-21-002533-index-headers.html	Edgar Link	pending
0001568276-21-002533-index.html	Edgar Link	pending
0001568276-21-002533.txt	Edgar Link	pending
0001568276-21-002533-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tenx-20210930.xsd	Edgar Link	pending
tenx-20210930_cal.xml	Edgar Link	unprocessable
tenx-20210930_def.xml	Edgar Link	unprocessable
tenx-20210930_lab.xml	Edgar Link	unprocessable
tenx-20210930_pre.xml	Edgar Link	unprocessable
tenx_10q.htm	Edgar Link	pending
tenx_10q_htm.xml	Edgar Link	completed
tenx_ex101.htm	Edgar Link	pending
tenx_ex102.htm	Edgar Link	pending
tenx_ex103.htm	Edgar Link	pending
tenx_ex311.htm	Edgar Link	pending
tenx_ex312.htm	Edgar Link	pending
tenx_ex321.htm	Edgar Link	pending
tenx_ex322.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TENX
TENAX THERAPEUTICS, INC. Stock $tenx

2021 Q4 Form 10-Q Financial Statement

#000156827621002533 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TENX TENAX THERAPEUTICS, INC. Stock $tenx

2021 Q4 Form 10-Q Financial Statement

#000156827621002533 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TENX
TENAX THERAPEUTICS, INC. Stock $tenx